文献速递血栓与止血

分子伴侣样苯丁酸钠改善由高频p.R294Q突变受损的凝血因子IX细胞内转运与活性

The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation.
PubMed 文献 · J Thromb Haemost · 2018-08-09

研究以重组凝血因子IX(FIX)变异体为模型,评估分子伴侣样化合物对I型血友病B错义突变所致分泌与转运障碍的 rescue 作用。结果显示苯丁酸钠(NaPBA)剂量依赖性改善p.R294Q变异体的高尔基体转运与分泌(从0.3±0.1%升至1.5±0.3%),并使其凝血活性升至3.0±0.9%。作者认为NaPBA可作为p.R294Q突变患者的低成本「个体化」候选治疗。

要点

  • 所有错义突变型rFIX分泌均低于野生型1%以下。
  • NaPBA仅对rFIX-294Q改善高尔基体转运并剂量依赖性促分泌。
  • rFIX-294Q凝血活性约为野生型2.0倍,NaPBA处理后达3.0±0.9%。

核心结论

  • 作者认为NaPBA可作为高频p.R294Q突变且替代治疗可及性降低患者的低成本「个体化」候选治疗。

研究设计与样本

  • 重组FIX变异体表达研究,比较p.R294Q与其他重型/中型I型血友病B复发突变,检测分泌(ELISA)、细胞内转运(免疫荧光)与活性(凝血试验)。

主要发现

  • 免疫荧光显示rFIX变异体滞留于内质网、高尔基体定位极少,提示细胞内转运受损。
  • 所有错义突变导致分泌受损,低于野生型rFIX的1%。
  • NaPBA剂量依赖性促进rFIX-294Q分泌,从0.3±0.1%升至1.5±0.3%。
  • rFIX-294Q在所有处理条件下凝血活性约为野生型rFIX的2.0倍。
  • NaPBA处理后rFIX-294Q凝血活性升至3.0±0.9%,作者称若在患者中达到此水平可改善出血表型。

关键数值与推荐

  • p.R294Q为最常见血友病B突变,约100例患者。
  • 所有错义突变rFIX分泌低于野生型1%。
  • NaPBA使rFIX-294Q分泌从0.3±0.1%升至1.5±0.3%。
  • rFIX-294Q凝血活性约为野生型2.0倍,处理后达3.0±0.9%。

临床怎么用

  • 作者认为NaPBA可作为p.R294Q突变且替代治疗可及性降低患者的候选「个体化」治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Essentials Missense mutations often impair protein folding, and thus intracellular trafficking and secretion. Cellular models of severe type I hemophilia B were challenged with chaperone-like compounds. Sodium phenylbutyrate improved intracellular trafficking and secretion of the frequent p.R294Q. The increased coagulant activity levels (∼3%) of p.R294Q would ameliorate the bleeding phenotype. SUMMARY: Background Missense mutations often impair protein folding and intracellular processing, which can be improved by small compounds with chaperone-like activity. However, little has been done in coagulopathies, where even modest increases of functional levels could have therapeutic implications. Objectives To rescue the expression of factor IX (FIX) variants affected by missense mutations associated with type I hemophilia B (HB) through chaperone-like compounds. Methods Expression studies of recombinant (r)FIX variants and evaluation of secreted levels (ELISA), intracellular trafficking (immunofluorescence) and activity (coagulant assays) before and after treatment of cells with chaperone-like compounds. Results As a model we chose the most frequent HB mutation (p.R294Q, ~100 patients), compared with other recurrent mutations associated with severe/moderate type I HB. Immunofluorescence studies revealed retention of rFIX variants in the endoplasmic reticulum and negligible localization in the Golgi, thus indicating impaired intracellular trafficking. Consistently, and in agreement with coagulation phenotypes in patients, all missense mutations resulted in impaired secretion (< 1% wild-type rFIX). Sodium phenylbutyrate (NaPBA) quantitatively improved trafficking to the Golgi and dose dependently promoted secretion (from 0.3 ± 0.1% to 1.5 ± 0.3%) only of the rFIX-294Q variant. Noticeably, this variant displayed a specific coagulant activity that was higher (~2.0 fold) than that of wild-type rFIX in all treatment conditions. Importantly, coagulant activity was concurrently increased to levels (3.0 ± 0.9%) that, if achieved in patients, would ameliorate the bleeding phenotype. Conclusions Altogether, our data detail molecular mechanisms underlying type I HB and candidate NaPBA as affordable 'personalized' therapeutics for patients affected by the highly frequent p.R294Q mutation, and with reduced access to substitutive therapy.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Pignani S, Todaro A, Ferrarese M, et al. The chaperone-like sodium phenylbutyrate improves factor IX intracellular trafficking and activity impaired by the frequent p.R294Q mutation. J Thromb Haemost. 2018. PMID: 29993188. doi:10.1111/jth.14236

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。